プロモーションスケジュール Reneo Pharmaceuticals, Inc.
詳細なスケジュール
簡易グラフ
会社について Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.| IPO date | 2021-04-08 |
|---|---|
| ISIN | US75974E1038 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://reneopharma.com |
| Цена ао | 1.82 |
| 1日あたりの価格変動: | 0% (1.82) |
|---|---|
| 週ごとの価格変動: | 0% (1.82) |
| 月ごとの料金変更: | 0% (1.82) |
| 3ヶ月間の価格変動: | 0% (1.82) |
| 半年間の価格変動: | +27.27% (1.43) |
| 年間の価格変動: | +10.98% (1.64) |
| 3年間の価格推移: | -60.94% (4.66) |
| 5年間の価格推移: | 0% (1.82) |
| 10年間の価格推移: | 0% (1.82) |
| 年初からの価格変動: | 0% (1.82) |
|
|
過小評価
|
効率
|
|||||||||||||||||||||||||||||||||||||
配当金
|
義務
|
成長の衝動
|
|||||||||||||||||||||||||||||||||||||
| 機関 | 音量 | 共有, % |
|---|---|---|
| NEA Management Company, LLC | 4785494 | 14.32 |
| Tang Capital Management, LLC | 3330000 | 9.96 |
| Carlyle Group Inc. | 2698957 | 8.08 |
| RiverVest Venture Management LLC | 2534220 | 7.58 |
| Octagon Capital Advisors LP | 2250000 | 6.73 |
| Bml Capital Management, LLC | 1314229 | 3.93 |
| Highbridge Capital Management, LLC. | 1121704 | 3.36 |
| Blackrock Inc. | 983304 | 2.94 |
| Vanguard Group Inc | 978889 | 2.93 |
| Aisling Capital Management LP | 886075 | 2.65 |
| ETF | 共有, % | 年間の利益率, % | 配当金, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.00768 | 17.09 | 1.54048 |
| Principal Healthcare Innovators ETF | 0.00594 | 618.5 | 0.8416 |
| Future Tech ETF | 0.00594 | 426.34 | 0.8416 |
| Invesco Nasdaq Biotechnology ETF | 0.00486 | 28.58 | 0.8565 |
| ProShares Ultra Nasdaq Biotechnology | 0.00333 | 51.7 | 0.85651 |
| スーパーバイザー | 役職 | 支払い | 生年 |
|---|---|---|---|
| Mr. Michael G. Grey | Founder & Executive Chairman | 100k | 1953 (72 年) |
| Mr. Gregory J. Flesher | President, CEO & Director | 569.7k | 1970 (55 年) |
| Mr. Michael P. Cruse | Chief Operating Officer | 535.47k | 1972 (53 年) |
| Ms. Jennifer P. Lam | SVP of Finance & Administration and Principal Financial & Accounting Officer | N/A | |
| Dr. Alejandro Dorenbaum M.D. | Chief Medical Officer | 466.23k | 1961 (64 年) |
住所: United States, Irvine. CA, 18575 Jamboree Road - Googleマップで開く, Yandexマップを開く
Webサイト: https://reneopharma.com
Webサイト: https://reneopharma.com
